The exorbitant cost of attending JPMorgan ? from hotels and flights to coffee and meeting space ? has long been a talking point for biopharma execs gathering in San Francisco every January. But as the industry?s signature networking confab fades out, the age-old question is once again in focus: Is it all worthwhile?
In a reflective article bemoaning the conference?s value and a negative stream of ?excesses,? Bruce Booth of Atlas Venture gave an emphatic answer: No.